View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2017	Mar. 05, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	HSDT
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		20,241,135
Entity Public Float			$ 99,372,392

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 5,562,000	$ 2,669,000
Receivables	704,000	225,000
Prepaid expenses and other current assets	352,000	556,000
Total current assets	6,618,000	3,450,000
Property, plant and equipment, net	173,000	0
Other assets	18,000	0
TOTAL ASSETS	6,809,000	3,450,000
Current liabilities
Accounts payable	3,479,000	2,161,000
Accrued liabilities	1,242,000	259,000
Derivative financial instruments	9,578,000	4,474,000
Total current liabilities	14,299,000	6,894,000
TOTAL LIABILITIES	14,299,000	6,894,000
Commitments and contingencies (Note 7)
STOCKHOLDERS’ DEFICIT
Common stock (Unlimited Class A common shares authorized); (20,178,226 shares issued and outstanding as of December 31, 2017 and 16,926,120 shares issued and outstanding as of December 31, 2016)	52,230,000	30,897,000
Additional paid-in capital	6,602,000	5,732,000
Accumulated other comprehensive income (loss)	47,000	(1,728,000)
Accumulated deficit	(66,369,000)	(38,345,000)
TOTAL STOCKHOLDERS’ DEFICIT	(7,490,000)	(3,444,000)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 6,809,000	$ 3,450,000

Consolidated Balance Sheets (Parenthetical) - shares	9 Months Ended	12 Months Ended
Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2016	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common Stock, Shares Authorized	Unlimited	Unlimited
Common Stock, Shares, Issued	16,926,120	20,178,226
Common Stock, Shares, Outstanding	16,926,120	20,178,226

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Operating expenses:
Research and development	$ 4,723	$ 14,387
General and administrative	5,651	8,466
Total operating expenses	10,374	22,853
Operating loss	(10,374)	(22,853)
Other income (expense):
Interest and other income	111
Change in fair value of derivative financial instruments	(2,480)	(3,443)
Foreign exchange gain (loss)	703	(1,728)
Total other expense	(1,666)	(5,171)
Net loss	(12,040)	(28,024)
Other comprehensive (loss)
Foreign currency translation adjustments	(728)	1,775
Comprehensive loss	$ (12,768)	$ (26,249)
Net loss per share
Basic and diluted	$ (0.72)	$ (1.50)
Weighted average shares outstanding
Basic and diluted	16,671,019	18,632,740

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Mar. 31, 2016	$ (15)	$ 24,348	$ 2,941	$ (26,305)	$ (999)
Beginning Balance, Shares at Mar. 31, 2016		14,438,627
Exercise of finder’s warrants	1,398	$ 1,549	(151)
Exercise of finder's warrants, Shares		365,120
Issuance of common stock in public offering and private placement	6,548	$ 6,548
Issuance of common stock in public offering and private placement, Shares		2,061,025
Issuance of warrants in public offering and private placement	1,504		1,504
Share issuance costs	(1,509)	$ (1,875)	366
Stock-based compensation expense	1,462		1,462
Fair value of non-employee vested options reallocated to derivative financial instruments	(268)		(268)
Agent compensation option exercise	1	$ 1
Agent compensation option exercise, Shares		150
Proceeds from the exercise of stock options and warrants	204	$ 326	(122)
Proceeds from the exercise of stock options and warrants, Shares		61,198
Net loss	(12,040)			(12,040)
Foreign currency translation adjustments	(729)				(729)
Ending Balance at Dec. 31, 2016	(3,444)	$ 30,897	5,732	(38,345)	(1,728)
Ending Balance, Shares at Dec. 31, 2016		16,926,120
Issuance of common stock in public offering	9,187	$ 9,187
Issuance of common stock in public offering, Shares		1,311,000
Issuance of common stock and warrants in private placement	11,691	$ 11,691
Issuance of common stock and warrants in private placement, Shares		1,446,016
Fair value of warrants issued in connection with the December 2017 financing classified as derivative financial instruments	(3,017)	$ (3,017)
Share issuance costs	(1,321)	(1,321)
Stock-based compensation expense	1,719		1,719
Proceeds from the exercise of stock options and warrants	2,588	$ 2,588
Proceeds from the exercise of stock options and warrants, Shares		492,826
Vesting of restricted stock units, net of taxes, shares		2,264
Reclassification of exercised stock options and warrants from additional paid-in capital		$ 849	(849)
Reclassification of liability classified warrants upon exercise	1,356	1,356
Net loss	(28,024)			(28,024)
Foreign currency translation adjustments	1,775				1,775
Ending Balance at Dec. 31, 2017	$ (7,490)	$ 52,230	$ 6,602	$ (66,369)	$ 47
Ending Balance, Shares at Dec. 31, 2017		20,178,226

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (12,040)	$ (28,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	0	17
Change in fair value of derivative financial instruments	2,480	3,443
Stock-based compensation expense	1,462	1,818
Unrealized foreign exchange loss (gain)	(641)	1,585
Changes in operating assets and liabilities:
Receivables	174	(479)
Prepaid expenses and other current assets	76	186
Account payable	345	1,318
Accrued liabilities	259	811
Net cash used in operating activities	(7,885)	(19,325)
Cash flows from investing activities
Purchase of Property, plant & equipment	0	(190)
Net cash used in investing activities	0	(190)
Cash flows from financing activities
Proceeds from the issuance of common stock and warrants	7,903	20,878
Share issuance costs	(1,509)	(1,248)
Proceeds from the exercise of stock options and warrants	1,603	2,588
Net cash provided by financing activities	7,997	22,218
Effect of foreign exchange rate changes on cash	(87)	190
Net increase in cash	25	2,893
Cash at beginning of period	2,644	2,669
Cash at end of period	2,669	5,562
Supplemental disclosure of non-cash cash activities
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplemental schedule of non-cash investing and financing activities
Share issuance costs included in accounts payable	0	73
Fair value of warrants issued to agent for services provided in conjunction with the April 2016 Offering	$ 366	$ 0

Description of Business

12 Months Ended

Dec. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

1.	DESCRIPTION OF BUSINESS

Helius Medical Technologies, Inc. (the “Company”) is engaged primarily in the medical technology industry focused on neurological wellness. The Company’s planned principal operations include the development, licensing and acquisition of unique and non-invasive platform technologies to amplify the brain’s ability to heal itself.

Many patients with brain injury or brain-related disease have disrupted neural networks that result in their brains being unable to correctly or efficiently carry neural impulses, which are responsible for directing bodily functions like movement control or sensory perception. Our first product in development, known as the portable neuromodulation stimulator or PoNS, device, is designed to enhance the brain’s ability to compensate for this damage. The PoNS Treatment is a combination of our PoNS device and functional, targeted physical or cognitive therapy, and is currently being developed for the treatment of movement, gait and balance disorders in patients with traumatic brain injury, or TBI, and other chronic neurological diseases.

The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. The Company is headquartered in Newtown, Pennsylvania.

The Company has two wholly-owned subsidiaries, Neurohabilitation Corporation (“NHC”) and Helius Medical Technologies (Canada), Inc. (“Helius Canada”).

The Company’s Class A common stock without par value (“common stock”) is currently listed on the Toronto Stock Exchange (the “TSX”). The Company’s common stock began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol “HSM”, and trading of the common stock subsequently moved to the TSX on April 18, 2016. The Company’s common stock also began trading on the OTC Markets (“OTCQB”) under the ticker symbol “HSDT” on February 10, 2015. The financial information is presented in United States Dollars.

Reverse Stock Split

Effective after the close of business on January 22, 2018, we completed a 1-for-5 reverse stock split of our Class A Common Stock. Since January 23, 2018, our Class A common stock has traded on a post-split basis on the OTCQB and Toronto Stock Exchange. All share and per share amounts in this Annual Report have been reflected on a post-split basis.

Going Concern

As of December 31, 2017, the Company had cash of $5.6 million. For the year ended December 31, 2017, the Company incurred a net loss of $28.0 million and, as of December 31, 2017 its accumulated deficit was $66.4 million. The Company has not generated any product revenues and has not achieved profitable operations. The Company expects to continue to incur operating losses and net cash outflows until such time as it generates a level of revenue to support its cost structure. There is no assurance that the Company will achieve profitable operations, and, if achieved, whether it will be sustained on a continued basis. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and satisfaction of liabilities in the ordinary course of business.

The Company intends to fund ongoing activities by utilizing its current cash and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosure of contingent assets and liabilities. Significant estimates include the assumptions used in the fair value pricing model for stock-based compensation and deferred income tax asset valuation allowance. Financial statements include estimates which, by their nature, are uncertain. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of Helius Medical Technologies, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

Concentrations of Credit Risk

The Company is subject to credit risk with respect to its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.

Receivables

Receivables are stated at their net realizable value. As of December 31, 2017, and 2016 receivables consisted primarily of Goods and Services Tax (“GST”) and Quebec Sales Tax (“QST) refunds related to the Company’s Canadian expenditures.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation. Depreciation is recognized using the straight-line method over the useful live of the related asset. Expenditures for maintenance and repairs, which do not improve or extend the expected useful life of the assets, are expensed to operations while major repairs are capitalized. The Company’s property, plant and equipment is comprised of leasehold improvements and software. The estimated useful life of its leasehold improvement is over the term of its lease of 5 years, while software has an estimated useful life of 3 to 5 years.

The following tables summarizes the Company property, plant and equipment as of December 31, 2017 (amounts in thousands). The Company had no property, plant and equipment as of December 31, 2016.

	As of December 31, 2017
Leasehold improvement	$	173
Software		17
		190
Less accumulated depreciation		(17	)
Total	$	173

Share-Based Payments

The Company accounts for all share-based payments and awards under the fair value-based method. The Company recognizes its stock-based compensation expense using the straight-line method.

The Company accounts for the granting of stock options to employees using the fair value method whereby all awards to employees are measured at fair value on the date of the grant. The fair value of all employee-related stock options is expensed over the requisite service period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Stock options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service conditions.

Share-based payment to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees are re-measured at each reporting period until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity-based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as of the grant date are measured and recognized at that date.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.

Foreign Currency

The functional currency of the Company and Helius Canada is the Canadian dollar (“CAD”) and the functional currency of NHC is the U.S. dollar (“USD”). The Company’s reporting currency is the U.S. dollar. Transactions in foreign currencies are recorded into the functional currency of the relevant subsidiary at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Revenues, expenses and cash flows are translated at the weighted-average rates of exchanges for the reporting period. The resulting currency translation adjustments are not included in the Company’s consolidated statements of operations for the reporting period, but rather are accumulated and gains and losses are recorded in foreign exchange gain (loss) within the consolidated statements of operations and comprehensive loss. The foreign exchange adjustment in the books of NHC relating to intercompany advances from Helius that are denominated in Canadian dollars is recorded in the consolidated statements of operations.

Income Taxes

The Company accounts for income taxes using the asset and liability method. The asset and liability method provide that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 Income Taxes regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of the tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of operations and comprehensive loss.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, development and manufacturing of clinical trial devices and devices for manufacturing testing, materials and supplies as well as regulatory costs. R&D costs are charged to operations when they are incurred.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates and manages its business within one operating and reportable segment. Accordingly, the Company reports the accompanying consolidated financial statements in the aggregate in one reportable segment.

Derivative Financial Instruments

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815, Derivatives and Hedging. The result of this accounting treatment is that the fair value of the derivative is marked-to-market at each balance sheet date and recorded as a liability or asset and the change in fair value is recorded in the consolidated statements of operations and comprehensive loss. The Company’s derivative financial instruments are comprised of warrants and non-employee stock options. Upon settlement of a derivative financial instrument, the instrument is marked to fair value at the settlement date and the fair value of the underlying instrument is reclassified to equity.

The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities/assets or as equity, is reassessed at the end of each reporting period. Derivative financial instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative financial instruments will be classified in the consolidated balance sheet as current if the right to exercise or settle the derivative financial instrument lies with the holder.

Fair Value Measurements

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The Company’s financial instruments recorded in its consolidated balance sheets consist primarily of cash, receivables, accounts payable, accrued liabilities, and derivative financial instruments. The book values of these instruments, with the exception of derivative financial instruments, approximate their fair values due to the immediate or short-term nature of these instruments.

The Company’s derivative financial instruments are classified as Level 3 within the fair value hierarchy and required to be recorded at fair value on a recurring basis. Unobservable inputs used in the valuation of these financial instruments include volatility of the underlying share price and the expected term. See Note 3 for the inputs used in the Black-Scholes option pricing model as of December 31, 2017 and 2016 and the roll forward of the derivative financial instruments related to the warrants and see Note 4 for the inputs used in the Black-Scholes option pricing model as of December 31, 2017 and 2016 for the roll forward of the derivative financial instruments related to the non-employee stock options.

The following table summarizes the Company’s derivative financial instruments within the fair value hierarchy as of December 31, 2017 and 2016 (amounts in thousands):

	Fair Value		Level 1		Level 2		Level 3
December 31, 2017
Liabilities:
Non-employee stock options	$	2,637		—		—	$	2,637
Warrants		6,941		—		—		6,941
December 31, 2016
Liabilities:
Non-employee stock options	$	1,617		—		—	$	1,617
Warrants		2,857		—		—		2,857

There were no transfers between any of the levels during the year ended December 31, 2017 and the nine months ended December 31, 2016.

Basic and Diluted Income (Loss) per Share

Earnings or loss per share (“EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted average of all potentially dilutive shares of common stock that were outstanding during the periods presented.

The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period.

EPS for convertible debt is calculated under the “if-converted” method. Under the if-converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.

The basic and diluted loss per share for the periods noted below is as follows (amounts in thousands, except for share and per share amounts):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Basic and Diluted
Numerator
Net loss	$	(28,024	)	$	(12,040	)
Denominator
Weighted-average common shares outstanding - basic and diluted		18,632,740			16,671,019
Basic and diluted net loss per share	$	(1.50	)	$	(0.72	)

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
Options outstanding		2,448,646		1,969,000
Warrants outstanding		2,379,919		2,017,252
Total		4,828,565		3,986,252

Reclassifications

Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this update change existing guidance related to accounting for employee share-based payments affecting the income tax consequences of awards, classification of awards as equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, with early adoption permitted. The updated accounting guidance was effective for the Company on January 1, 2017 and it did not have a material effect on our consolidated financial statements and any deferred tax benefits would be offset by a valuation allowance.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use, or ROU, model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated statement of operations. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the consolidated financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the standard on our consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which was further amended through various updates issued by the FASB thereafter. The amendments of Topic 606 completed the joint effort between the FASB and the IASB, to develop a common revenue standard for GAAP and IFRS, and to improve financial reporting. The guidance under Topic 606 provides that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for the goods or services provided and establishes a five-step model to be applied by an entity in evaluating its contracts with customers. The Company does not have any revenues or contracts with customers and will need to evaluate the impact of Topic 606 on its results of operations, cash flows and financial position should a revenue generating transaction arise in the future. While the Company will adopt Topic 606 on January 1, 2018 (and will do so on a modified retrospective basis), the adoption will have no impact on the Company’s consolidated financial statements.

Common Stock and Warrants

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Common Stock and Warrants

3.	COMMON STOCK AND WARRANTS

As of December 31, 2017, the Company’s certificate of incorporation authorized the Company to issue unlimited Class A common shares without par value. Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. No dividends have been declared through December 31, 2017. In the event of a liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

The Company is subject to a stockholders’ agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

On October 9, 2015, the Company entered into a $7.0 million funding commitment with A&B (HK) Company Limited (“A&B”), in the form of a convertible promissory note consisting of an initial $2.0 million note and a $5.0 million funding commitment. On October 9, 2015, the Company received the conversion notice on the promissory note and in November 2015, the Company issued 416,666 shares of common stock at a price of $4.80 per share and 208,333 warrants exercisable at $7.20 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on November 10, 2015. On December 29, 2015, the Company drew down the $5.0 million funding commitment through the issuance of 1,111,111 shares of common stock at a price of $4.50 per share and 555,556 warrants exercisable at $6.75 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on January 7, 2016. In November 2017, A&B exercised 208,333 warrants at a price of $7.20 and the Company received gross cash proceeds of $1.5 million upon the exercise.

On April 18, 2016, the Company closed its short form prospectus offering in Canada and a concurrent U.S. private placement (the “April 2016 Offering”) of units (the “Units”) with gross proceeds to the Company of $7.2 million through the issuance of Units at a price of CAD$5.00 per Unit. Each Unit consists of one Class A common share in the capital of the Company (a “Common Share’) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each warrant entitles the holder thereof to acquire one additional Common Share at an exercise price of CAD$7.50 on or before April 18, 2019. Mackie Research Capital Corporation (the “Agent”) acted as agent and sole bookrunner in connection with the April 2016 Offering. The Company paid the Agent a cash commission of $0.3 million and has granted to the Agent compensation options exercisable to purchase 87,210 Units at an exercise price of CAD$5.00 per Unit for a period of 24 months from the closing of the April 2016 Offering. The Company incurred other cash issuance costs of $1.1 million related to this offering.

On May 2, 2016, the Company closed the sale of the additional units issued pursuant to the exercise of the over-allotment option granted to the Agent in connection with the April 2016 Offering. The April 2016 Offering was made pursuant to a short form prospectus filed with the securities regulatory authorities in each of the provinces of Canada, except Québec. Pursuant to the exercise of the over-allotment option, the Company issued an additional 218,025 units at a price of CAD $5.00 per unit for additional gross proceeds to the Company of $0.9 million, bringing the total aggregate gross proceeds to the Company under the Offering to $8.1 million. Each over-allotment unit consisted of one Class A common share in the capital of the Company and one half of one Common Share purchase warrant. Each over-allotment warrant entitles the holder thereof to acquire one additional over-allotment Common Share at an exercise price of CAD $7.50 on or before April 18, 2019. In connection with the closing of the over-allotment option, the Company paid the Agent a cash commission of $0.1 million and granted to the Agent compensation options exercisable to purchase 13,081 over-allotment units at an exercise price of CAD $5.00 per unit for a period of 24 months from the closing of this Offering.

The warrants issued in each of the April 18, 2016 and May 2, 2016 closings are classified within equity. The proceeds from the Offering were allocated on a relative fair value basis between the Class A common shares and the warrants issued. The compensation options are accounted for as warrants. These warrants represent additional share issuance costs and are recorded within shareholders’ deficit in the Company’s consolidated balance sheets at their fair value.

The fair value of the warrants granted in the April 2016 Offering were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:


Stock price	CAD$5.45
Exercise price	CAD$7.50
Warrant term	3.0 years
Expected volatility		83.83	%
Risk-free interest rate		0.60	%
Dividend rate		0.00	%

The fair value of the compensation options granted during the April 2016 Offering were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:


Stock price	CAD$6.80
Exercise price	CAD$5.00
Option term	2.0 years
Expected volatility		126.76	%
Risk-free interest rate		0.61	%
Dividend rate		0.00	%

On June 6, 2016, the Company received proceeds of USD $1.4 million from the exercise of 365,120 outstanding warrants which were issued in connection with the Company’s private placement of subscription receipts that closed on May 30, 2014. The remaining 1,320,880 warrants issued in this offering expired unexercised.

On February 16, 2017, the Company completed an underwritten registered public offering and issued an aggregate of 1,311,000 shares of common stock for gross proceeds of $9.2 million. The offering was made by means of written prospectuses and prospectus supplements, dated February 9, 2017, that form part of the Company’s existing Canadian multi-jurisdictional disclosure system (“MJDS”) short-form base shelf prospectus dated January 26, 2017, in Canada, and U.S. shelf registration statement on Form S-3 that became effective on January 6, 2017, in the U.S. The Company incurred cash issuance costs of $1.2 million in connection with this offering.

On June 28, 2017, the Company completed a non-brokered private placement of 800,000 shares of common stock for gross proceeds of $5.4 million. The Company incurred approximately $9 thousand in share issuance cost related to the private placement.

In December 2017, the Company completed a three-tranche non-brokered private placement (the “December 2017 financing”) of 646,016 units for gross proceeds of approximately $6.3 million. Each unit consisted of one share of Class A common stock of the Company at a price of $9.80 per share, and one share purchase warrant. Each warrant entitles the holder to acquire one additional share of Class A common stock of the Company, exercisable for a period of 36 months following the closing of the private placement at an exercise price of USD$12.25 per warrant share. The first tranche, which closed on December 22, 2017, was for 270,915 units for which the Company received gross proceeds of approximately $2.6 million. The second tranche which closed on December 28, 2017, was for 171,020 units for which the Company received approximately $1.7 million, while the third tranche which closed on December 29, 2017, was for 204,081 units for which the Company received $2.0 million. The Company accrued $0.1 million in share issuance costs related to the December 2017 financing.

The fair value of the warrants granted in the December 2017 financing were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 22, 2017			December 28, 2017			December 29, 2017
Stock price	$	10.60		$	12.45		$	12.32
Exercise price	$	12.25		$	12.25		$	12.25
Warrant term	3.0 years			3.0 years			3.0 years
Expected volatility		60.24	%		60.24	%		60.24	%
Risk-free interest rate		2.01	%		2.00	%		1.98	%
Dividend rate		0.00	%		0.00	%		0.00	%

Pursuant to the guidance of ASC 815 Derivatives and Hedging, the Company determined that certain warrants issued in 2015, warrants related to the funding commitment with A&B in 2016, as well as warrants issued in the December 2017 financing are accounted for as liabilities because they were not considered to be indexed to the Company’s stock due to the exercise price being denominated in a currency other than the Company’s functional currency. Consequently, the Company determined the fair value of each warrant issuance using the Black-Scholes option pricing model, with the remainder of the proceeds allocated to the common shares.

The following table summarizes warrants that the Company accounts for as liabilities for the year ended December 31, 2017 and nine months ended December 31, 2016 (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Fair value of warrants at beginning of period	$	2,857		$	1,205
Issuance of warrants		3,016			—
Exercise of warrants		(1,200	)		—
Change in fair value of warrants during the period		2,268			1,652
Fair value of warrants at end of period	$	6,941		$	2,857

The warrants are required to be re-valued at the end of each reporting period, with the change in fair value of the liability recorded as a gain or loss in the change of fair value of derivative financial instruments, included in other income (expense) in the Company’s consolidated statements of operations and comprehensive loss. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The fair value of warrants as of December 31, 2017 and 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2017			December 31, 2016
Stock price	$	12.32		$	6.90
Exercise price	$	10.25		$	8.10
Warrant term	1.91 years			1.89 years
Expected volatility		62.20	%		94.97	%
Risk-free interest rate		1.83	%		0.79	%
Dividend rate		0.00	%		0.00	%

The following is a summary of warrant activity during the year ended December 31, 2017 and nine months ended December 31, 2016:

	Number of Warrants						Weighted-Average Exercise Price
	CAD			US			CAD		US
Outstanding as of April 1, 2016		1,686,000			905,721		$	5.00	$	8.10
Granted		1,030,587			—			7.50
Granted (Agent Compensation)		100,291			—			5.00
Expired		(1,320,880	)		—			5.00
Exercised		(384,468	)		—			5.10
Outstanding as of December 31, 2016		1,111,530			905,721			7.30		8.10
Granted		25,063			646,016			7.50		12.25
Exercised		(125,088	)		(208,333	)		6.50		7.20
Outstanding and exercisable as of December 31, 2017		1,011,505			1,343,404		$	7.38	$	10.25

The following table summarizes the Company’s warrants outstanding and exercisable as of December 31, 2017:

Number of Warrants Outstanding		Exercise Price	Expiration Date
	90,406	US$15.00	April 30, 2018
	33,546	US$15.00	June 26, 2018
	3,795	US$10.75	June 26, 2020
	12,576	US$15.00	July 17, 2018
	1,509	US$10.75	July 17, 2020
	555,556	US$6.75	December 29, 2018
	961,489	CAD$7.50	April 18, 2019
	50,015	CAD$5.00	April 18, 2018
	270,915	US$12.25	December 22, 2020
	171,020	US$12.25	December 28, 2020
	204,081	US$12.25	December 29, 2020
	2,354,908

Share Based Payments

12 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share Based Payments

4.	SHARE BASED PAYMENTS

On June 18, 2014, the Company’s Board of Directors authorized and approved the adoption of the 2014 Stock Incentive Plan (“2014 Plan”), under which an aggregate of 2,421,603 shares of common stock may be issued. Pursuant to the terms of the 2014 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units and deferred stock units. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Company’s Board of Directors. On August 22, 2017, the Company’s Board of Directors approved the amended and restated 2014 Plan to correct for a formulaic error included in the deemed net stock and cashless exercise equation within the 2014 Plan. This amendment had no impact on the Company’s consolidated financial statements. As of December 31, 2017, the Company had 40,000 shares of common shares remaining available for grant under the 2014 Plan.

On August 8, 2016, the Company’s Board of Directors authorized and approved the adoption of the 2016 Omnibus Incentive Plan (“2016 Plan”), under which an aggregate of 3,000,000 shares of common stock may be issued. Pursuant to the terms of the 2016 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units, stock equivalent units and performance-based cash awards. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Company’s Board of Directors.

As of December 31, 2017, there were an aggregate of 2,693,614 shares of common stock remaining available for grant under the 2016 Plan.

The following is a summary of stock option activity for the year ended December 31, 2017 and nine months ended December 31, 2016:

				Weighted Average		Aggregate
				Exercise Price		Intrinsic Value
	Number of Options			(CAD)		(CAD)
Outstanding as of April 1, 2016		1,335,072		$	5.40	$	1,581
Granted		707,000			6.90
Forfeited		(6,250	)		3.00
Cancelled		(24,822	)		3.00
Exercised		(42,000	)		3.00
Outstanding as of December 31, 2016		1,969,000			6.00		8,218
Granted		868,902			11.15
Forfeited		(153,067	)		11.45
Cancelled		(62,689	)		13.75
Exercised ⁽¹⁾		(173,500	)		5.15
Outstanding as of December 31, 2017		2,448,646		$	7.35	$	21,089
Exercisable as of December 31, 2017		1,451,739		$	5.70	$	14,892

(1) For the year ended December 31, 2017, 20,000 stock options were exercised on a cashless basis resulting in 14,095 common shares being withheld.

The Company has adopted the simplified method prescribed by the SEC in SAB Topic 14 with respect to estimating the expected term of its stock options as its limited share purchase option history does not provide a reasonable basis to estimate the expected terms. Expected volatility was determined by reference to the average volatility rates of other companies in the same industry due to the Company’s limited trading history. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2017 and nine months ended December 31, 2016 was $1.3 million and $0.1 million, respectively.

The following table summarizes stock options outstanding and exercisable by employees and directors as of December 31, 2017:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	360,000	June 18, 2019		1.46	$	3.00	$	1.00		360,000
	80,000	June 18, 2019		1.46	$	3.00	$	1.32		80,000
	20,000	December 8, 2019		1.94	$	14.60	$	6.55		20,000
	80,000	December 8, 2019		1.94	$	14.80	$	6.46		80,000
	20,000	March 16, 2020		2.21	$	16.00	$	7.09		20,000
	8,500	August 14, 2020		2.62	$	4.90	$	1.94		8,500
	150,000	October 21, 2020		2.81	$	4.20	$	1.80		112,500
	20,000	December 31, 2020		3.00	$	6.20	$	2.49		20,000
	595,000	July 13, 2020		2.53	$	6.95	$	3.23		396,666
	20,000	August 8, 2020		2.61	$	6.55	$	3.23		10,000
	617,000	April 17, 2027		9.30	$	10.80	$	7.76		-
	6,146	May 18, 2027		9.38	$	10.00	$	5.23		3,073
	10,000	May 18, 2027		9.38	$	10.00	$	7.63		-
	30,000	August 8, 2027		9.61	$	13.15	$	8.86		-
	2,016,646									1,110,739

As of December 31, 2017, and 2016, the unrecognized compensation cost related to non-vested stock options outstanding for employees and directors, was $4.9 million and $1.3 million, respectively, to be recognized over a weighted-average remaining vesting period of approximately 2.6 years and 1.41 years, respectively. The Company recognizes compensation expense for only the portion of awards that are expected to vest.

During the fourth quarter of 2017, upon a review of the Company’s equity compensation awards granted under the 2016 Plan it determined that it had inadvertently exceeded the annual per-person sub-limits involving certain awards previously made to a current executive officer. The aggregate amount of common stock represented by this excess award, which consisted of stock options, was 60,000 shares. This excess award was deemed to have been granted outside of the 2016 Plan and as such the Company applied liability accounting to the awards. As a result, this excess award will be remeasured at each reporting period untill such time that the Company’s shareholders approve the excess award at which time the liability will be reclassified to additional paid-in capital and the unrecognized fair value calculated for the excess award as of the date of shareholders’ approval will be recognized as compensation expense ratably over the remaining requisite service period for the excess award.

For the year ended December 31, 2017 and the nine months ended December 2016, the Company granted 673,902 and 625,000 stock options, respectively, to employees and directors at a weighted average exercise price of CAD$10.87 and CAD$6.94, respectively. The fair value of employee and director stock options granted for the year ended December 31, 2017 and the nine months ended December 31, 2016 had a weighted average grant date fair value of CAD$4.34 and $2.60 per option, respectively, and they were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Stock price	CAD$10.40			CAD$6.95
Exercise price	CAD$10.85			CAD$6.95
Expected term	6.25 years			2.5 years
Expected volatility		90.84	%		77.92	%
Risk-free interest rate		1.06	%		0.49	%
Dividend rate		0.00	%		0.00	%

Non-Employee Stock Options

For the year ended December 31, 2017, the Company granted 195,000 stock options at a weighted average exercise price of CAD$12.20, of which 185,000 were either cancelled or forfeited to non-employees. For the nine months ended December 31, 2016, the Company granted 82,000 stock options to non-employees at a weighted average exercise price of CAD$6.70. The fair value of non-employee stock options granted for the year ended December 31, 2017 and the nine months ended December 31, 2016 had a weighted average grant date fair value of CAD$3.88 and $3.23 per option, respectively, and they were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Stock price	CAD$12.15			CAD$9.60
Exercise price	CAD$12.20			CAD$6.75
Option term	10 years			3.75 years
Expected volatility		91.02	%		84.16	%
Risk-free interest rate		1.60	%		0.98	%
Dividend rate		0.00	%		0.00	%

The following table summarizes stock options outstanding and exercisable by non-employees as of December 31, 2017:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	160,000	June 18, 2019		1.46	$	3.00	$	1.32		160,000
	30,000	December 8, 2019		1.94	$	14.60	$	8.25		30,000
	82,000	October 3, 2020		2.76	$	6.75	$	4.00		41,000
	110,000	October 28, 2020		2.83	$	4.20	$	2.20		110,000
	20,000	May 18, 2027		9.38	$	10.00	$	8.69		-
	15,000	August 8, 2027		9.61	$	13.15	$	11.70		-
	15,000	November 6, 2027		9.85	$	20.65	$	19.93		-
	432,000									341,000

As of December 31, 2017, the unrecognized compensation cost related to non-vested stock options outstanding for non- employees was $0.4 million to be recognized over a weighted-average remaining vesting period of approximately 1.93 years, respectively. As of December 31, 2016, the Company had no unrecognized compensation cost related to non-vested stock options outstanding for non-employees. The Company recognizes compensation expense for only the portion of awards that are expected to vest.

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for NHC are required to be accounted for as derivative financial instruments once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than NHC’s functional currency. Stock options awarded to non-employees that have not vested are re-measured at their respective fair values at each reporting period and accounted for as equity awards until the terms associated with their vesting requirements have been met. The changes in fair value of the unvested non-employee awards are reflected in their respective operating expense classification in the Company’s consolidated statements of operations and comprehensive loss.

The non-employee stock options that are accounted for as liabilities are summarized as follows (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Fair value of non-employee stock options at beginning of period	$	1,617		$	521
Reallocation of vested non-employee stock options		-			268
Exercised		(156	)		-
Cancelled		(294	)		-
Change in fair value of non-employee stock options during the period		1,470			828
Fair value of non-employee stock options at end of period	$	2,637		$	1,617

The non-employee stock options that have vested are required to be re-valued with the change in fair value recorded as a gain or loss in the change of fair value of derivative financial instruments and included in other income (expense) in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the stock options will continue to be classified as a derivative financial instrument until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as such.

The fair value of non-employee liability classified awards as of December 31, 2017 and 2016 were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	December 31, 2017			December 31, 2016
Stock price	CAD$15.95			CAD$9.60
Exercise price	CAD$4.30			CAD$6.15
Expected life	1.51 years			2.59 years
Expected volatility		61.58	%		87.61	%
Risk-free interest rate		1.61	%		0.79	%
Dividend rate		0.00	%		0.00	%

Restricted Stock Units

During the second quarter of 2017, the Company granted restricted stock units to certain employees under the 2016 Plan that vest over a three-year period, with 25% vesting immediately. The fair value of the restricted stock units is based on the closing price of the Company’s common stock on the date of grant.

The following is a summary of the Company’s restricted stock unit activity for the year ended December 31, 2017:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit (CAD)
Outstanding as of January 1, 2017		-		$	-
Granted		8,097			10.00
Forfeited		(3,182	)
Outstanding as of December 31, 2017		4,915		$	10.00
Vested as of December 31, 2017 ⁽¹⁾		2,987		$	10.00

(1) includes 723 RSUs withheld for taxes

Stock-based compensation expense is classified in the Company’s consolidated statements of operations and comprehensive loss as follows (amounts in thousands):

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
Research and development	$	343	$	107
General and administrative		1,475		1,355
	$	1,818	$	1,462

Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accrued Expenses

5.	ACCRUED EXPENSES

Accrued expenses consisted of the following (amounts in thousands):

	December 31, 2017		December 31, 2016
Employees benefits	$	442	$	259
Advance from U.S Army		233		-
Legal expense		343		-
Rent		97		-
Professional services		88		-
Severance		38		-
Other		1		-
	$	1,242	$	259

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

6.	INCOME TAXES

The components of net loss are as follows (amounts in thousands):

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
U.S.	$	24,980	$	11,082
Non-U.S.		3,044		958
	$	28,024	$	12,040

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision is as follows (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Statutory tax rate		34.00	%		34.00	%
Net loss before income taxes	$	28,024		$	12,040
Expected income tax recovery	$	(9,528	)	$	(4,094	)
Increase (decrease) in income tax recovery resulting from:
Derivative liability		1,171			843
Share based payments		453			467
Other permanent difference		(446	)		(420	)
Effect of change in statutory rate		5,938			—
State deferred change		(2,050	)		—
Foreign income taxed at foreign rate		118			77
Increase in valuation allowance		4,344			3,127
Income tax expense	$	—		$	—

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows (amounts in thousands):

	December 31, 2017			December 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$	11,382		$	7,626
Tax credits		1,243			702
Stock compensation		1,414			1,726
Other		530			170
Valuation allowance		(14,569	)		(10,224	)
Net deferred income tax asset	$	—		$	—

As of December 31, 2017, the Company has accumulated non-capital losses totaling $6.0 million in Canada and net operating losses of $39.0 million in the U.S., which may be available to carry forward and offset future years’ taxable income. The losses expire in various amounts starting in 2033.

Under the provisions of the Internal Revenue Code, the net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Section 382 of the Internal Revenue Code, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.

On December 22, 2017 the U.S. Government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“The Act”). The Act makes broad changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S federal corporate tax rate from 35% to 21%; (ii) eliminating the corporate alternative minimum tax; (iii) creating a new limitation on deductible interest expense; (iv) creating the base erosion and anti-abuse tax, a new minimum tax; (v) limitation on the deductibility of certain executive compensation; (vi) enhancing the option to claim accelerated depreciation deductions on qualified property, and (vii) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017.

The Act reduces the corporate tax rate to 21%, effective January 1, 2018. The accounting for this portion of The Act has caused a reduction to the Company’s net deferred tax assets before valuation allowance of $5.9 million for the year ended December 31,2017. However, the Company maintains a full valuation allowance against its deferred tax assets. As a result, the $5.9 million reduction to the Company’s deferred tax assets is offset by a corresponding $5.9 million reduction in the Company’s valuation allowance, resulting in no net impact to the Company’s tax provision.

The Company has not completed its determination of the accounting implications of The Act on its tax accruals. However, the Company has reasonably estimated the effects of The Act as described above as of December 31, 2017, primarily comprised of the remeasurement of federal net deferred tax assets resulting from the permanent reduction in the U.S. statutory corporate tax rate to 21% from 34%. As the Company completes its analysis of The Act, collect and prepare necessary data, and interpret any additional guidance issued by the U.S. Treasury Department, the IRS, and other standard-setting bodies, the Company may make adjustments to the provisional amounts recorded as of December 31, 2017. However, those adjustments are not anticipated to have a material impact on the Company’s tax provision.

Uncertain Tax Positions

The Company has adopted certain provisions of ASC 740, “Income Taxes”, which prescribes a recognition threshold and measurement attribute for the recognition and measurement of tax positions taken or expected to be taken in income tax returns. The provisions also provide guidance on the de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions.

The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the expiration of the respective statutes of limitation. The Company currently has no tax years under examination.

As of December 31, 2017, the Company does not have an accrual relating to uncertain tax positions. It is not anticipated that unrecognized tax benefits would significantly increase or decrease within 12 months of the reporting date.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	COMMITMENTS AND CONTINGENCIES

(a)

On January 22, 2013, the Company entered into a license agreement with Advanced NeuroRehabilitation, LLC (“ANR”) for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 3,207,005 shares of common stock, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology. The Company has not made any royalty payments to date under this agreement.

(b)

On October 30, 2017, NHC amended the Asset Purchase Agreement with A&B which specified that if the Company fails to obtain FDA marketing authorization for commercialization of or otherwise fails to ensure that the PoNS device is available for purchase by the U.S. Government by December 31, 2021, the Company would be subject to a $2.0 million contract penalty payable to A&B, unless the Company receives an exemption for the requirement of FDA marketing authorization from the US Army Medical Material Agency. Based on this amendment the Company has determined that the possibility of a payment under this contractual penalty is remote.

(c)

In November 2014, the Company signed a development and distribution agreement with Altair LLC to apply for registration and distribution of the PoNS device in the territories of the former Soviet Union. The Company will receive 7% royalty on sales of the devices within the territories. However, there is no assurance that such commercialization will occur.

(d)

In March 2017, the Company entered into a lease for office space in Newtown, Pennsylvania. The initial term of the lease is from July 1, 2017 through December 31, 2022, with an option to extend until 2027. In July 2017, the Company amended the contract to commence the lease on July 17, 2017 through January 16, 2023, with an option to extend until January 2028. Monthly rent plus utilities will be approximately $20,000 per month beginning in January 2018 with a 3% annual increase.

The future minimum lease payments related to the Company’s non-cancellable operating lease commitments were as follows (amounts in thousands):

For the Year Ending December 31,
2018	$	231
2019		246
2020		253
2021		260
2022		267
Thereafter		12
	$	1,269

(e)

On December 29, 2017, NHC, a wholly owned subsidiary of the Company entered into a Manufacturing and Supply Agreement (“MSA”) with Key Tronic Corporation (“Key Tronic”), for the manufacture and supply of the Company’s PoNS device based upon the Company’s product specifications as set forth in the MSA. Per the agreement, the Company shall provide to Key Tronic a rolling forecast for the procurement of parts and material and within normal lead times based on estimated delivery dates for the manufacture of the PoNS device. The term of the agreement will be for three-years and will automatically renew for additional consecutive terms of one year, unless cancelled by either party upon 180-day written notice to the other party prior to the end of the then current term. As of December 31, 2017, no initial forecast had been provided to Key Tronic by the Company.

Related Party Transactions

12 Months Ended

Dec. 31, 2017

Related Party Transactions

8.	RELATED PARTY TRANSACTIONS

For the year ended December 31, 2017, the Company paid approximately $16 thousand in consulting fee to a director of the Company. For the nine months ended December 31, 2016, the Company paid $0.1 million in consulting fees to certain directors of the Company.

During April 2016, the Company entered into a consulting agreement with Montel Media, Inc. (“Montel Media”), pursuant to which Montel Media provides consulting services for the promotion of the Company’s clinical trials and ongoing media and marketing strategies. Under the agreement, Montel Media receives $15 thousand per month. For the year ended December 31, 2017 and the nine months ended December 31, 2016, the Company paid Montel Media $0.2 million and $0.1 million, respectively, pursuant to the consulting agreement. Montel Media is owned by Montel Williams, who beneficially owns greater than 5% of the Company’s common stock.

For the year ended December 31, 2017 and nine months ended December 31, 2016, an expense of $0.4 million and $0.2 million, respectively, was included in the change in fair value of derivative financial instruments as the fair value of stock-based compensation attributed to the options granted to a director for consulting services rendered with respect to the design and development of the PoNS device.

The Company’s Chief Medical Officer is a founding member of Clinvue LLC, a company that provides regulatory advisory services for the Company. During the year ended December 31, 2017, the Company paid Clinvue LLC approximately $0.1 million for consulting services. For the nine months ended December 31, 2016, the Company made no payment to Clinvue LLC.

In connection with the December 2017 private placement, the Company’s Chief Executive Officer, its Chief Financial Officer/Chief Operating Officer, two directors and A&B, a greater than 5% owner of the Company’s shares outstanding subscribed in the private placement. The following table summarizes their participation (subscription amount in thousands):

	Units Purchased		Subscription Amount
A&B (HK) Company Ltd.		204,081	$	2,000
Director 1		76,530		750
Director 2		51,019		500
CEO		25,510		250
CFO/COO		15,816		155
		372,956	$	3,655

Sole-Source Cost-Sharing Agreement and Cooperative Research and Development Agreement

12 Months Ended

Dec. 31, 2017

Disclosure Of Cost Sharing Agreement And Cooperative Research And Development Agreement [Abstract]

Sole-Source Cost-Sharing Agreement and Cooperative Research and Development Agreement

9.	SOLE-SOURCE COST-SHARING AGREEMENT AND COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT

In July 2015, the Company entered into a sole source cost sharing agreement with the U.S. Army Medical Research and Materiel Command (“USAMRMC”). Under the terms of the contract, the USAMRMC will reimburse the Company up to a maximum of $3.0 million to conduct a registrational trial investigating the safety and effectiveness of the PoNS device for the treatment of chronic balance deficits due to mild to moderate traumatic brain injury. Reimbursement of expenses under the agreement is based on a schedule of milestones related to the completion of subjects in the trial. The original contract expired on December 31, 2016; however, the Company extended the contract agreement through December 31, 2017. On November 7, 2017, the Company received another extension of the contract agreement to December 31, 2018. As of December 31, 2017, the Company has received a total of $3.0 million with respect to expenses reimbursed for amounts owed to the Company for completion of development milestones, of which $0.2 million of the total received has been recorded as an advance against the fifth and final milestone. All reimbursement amounts received are credited directly to the accounts in which the original expense is recorded, including research and development, wages and salaries, and legal expenses. In addition, during the third quarter of 2017, the Company announced the execution of an extension to its Cooperative Research and Development Agreement (“CRADA”) with the USAMRMC through 2018 and extended the deadline for commercialization of the PoNS device to December 31, 2021.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	10.SUBSEQUENT EVENTS A&B Warrant Exercise and License Agreement On February 28, 2018, A&B executed their notice to exercise 555,556 warrants issued on January 7, 2016, at an exercise price of $6.75 for gross proceeds to the Company of approximately $3.8 million. On March 2, 2018, the Company, NHC and A&B entered into an agreement to negotiate an exclusive license agreement to grant A&B exclusive license rights to commercialize the PoNS device and components in additional territories in Asia.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Reverse Stock Split

Going Concern

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Use of Estimates

Principles of Consolidation

Concentrations of Credit Risk

Receivables

Property, Plant and Equipment

The following tables summarizes the Company property, plant and equipment as of December 31, 2017 (amounts in thousands). The Company had no property, plant and equipment as of December 31, 2016.

	As of December 31, 2017
Leasehold improvement	$	173
Software		17
		190
Less accumulated depreciation		(17	)
Total	$	173

Stock-Based Compensation

Share-Based Payments

The Company accounts for all share-based payments and awards under the fair value-based method. The Company recognizes its stock-based compensation expense using the straight-line method.

Foreign Currency

Income Taxes

Research and Development Expenses

Segment Information

Derivative Financial Instruments

Fair Value Measurements

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The following table summarizes the Company’s derivative financial instruments within the fair value hierarchy as of December 31, 2017 and 2016 (amounts in thousands):

	Fair Value		Level 1		Level 2		Level 3
December 31, 2017
Liabilities:
Non-employee stock options	$	2,637		—		—	$	2,637
Warrants		6,941		—		—		6,941
December 31, 2016
Liabilities:
Non-employee stock options	$	1,617		—		—	$	1,617
Warrants		2,857		—		—		2,857

There were no transfers between any of the levels during the year ended December 31, 2017 and the nine months ended December 31, 2016.

Basic and Diluted Income (Loss) per Share

The basic and diluted loss per share for the periods noted below is as follows (amounts in thousands, except for share and per share amounts):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Basic and Diluted
Numerator
Net loss	$	(28,024	)	$	(12,040	)
Denominator
Weighted-average common shares outstanding - basic and diluted		18,632,740			16,671,019
Basic and diluted net loss per share	$	(1.50	)	$	(0.72	)

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
Options outstanding		2,448,646		1,969,000
Warrants outstanding		2,379,919		2,017,252
Total		4,828,565		3,986,252

Reclassifications

Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Property, Plant and Equipment

The following tables summarizes the Company property, plant and equipment as of December 31, 2017 (amounts in thousands). The Company had no property, plant and equipment as of December 31, 2016.

	As of December 31, 2017
Leasehold improvement	$	173
Software		17
		190
Less accumulated depreciation		(17	)
Total	$	173

Summary of Derivative Financial Instruments for Non-employee Stock Options

The following table summarizes the Company’s derivative financial instruments within the fair value hierarchy as of December 31, 2017 and 2016 (amounts in thousands):

	Fair Value		Level 1		Level 2		Level 3
December 31, 2017
Liabilities:
Non-employee stock options	$	2,637		—		—	$	2,637
Warrants		6,941		—		—		6,941
December 31, 2016
Liabilities:
Non-employee stock options	$	1,617		—		—	$	1,617
Warrants		2,857		—		—		2,857

Summary of Basic and Diluted Loss per Share

The basic and diluted loss per share for the periods noted below is as follows (amounts in thousands, except for share and per share amounts):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Basic and Diluted
Numerator
Net loss	$	(28,024	)	$	(12,040	)
Denominator
Weighted-average common shares outstanding - basic and diluted		18,632,740			16,671,019
Basic and diluted net loss per share	$	(1.50	)	$	(0.72	)

Summary of Outstanding Securities Excluded from Computation of Diluted Weighted Shares Outstanding

The following outstanding securities have been excluded from the computation of diluted weighted shares outstanding for the periods noted below, as they would have been anti-dilutive:

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
Options outstanding		2,448,646		1,969,000
Warrants outstanding		2,379,919		2,017,252
Total		4,828,565		3,986,252

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Common Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value of Warrants Granted in Offering/Financing Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

The fair value of warrants as of December 31, 2017 and 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 31, 2017			December 31, 2016
Stock price	$	12.32		$	6.90
Exercise price	$	10.25		$	8.10
Warrant term	1.91 years			1.89 years
Expected volatility		62.20	%		94.97	%
Risk-free interest rate		1.83	%		0.79	%
Dividend rate		0.00	%		0.00	%

Fair Value of Compensation Options Granted During Offering Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

The fair value of the compensation options granted during the April 2016 Offering were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:


Stock price	CAD$6.80
Exercise price	CAD$5.00
Option term	2.0 years
Expected volatility		126.76	%
Risk-free interest rate		0.61	%
Dividend rate		0.00	%

Summary of Warrants Accounts for Liabilities

The following table summarizes warrants that the Company accounts for as liabilities for the year ended December 31, 2017 and nine months ended December 31, 2016 (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Fair value of warrants at beginning of period	$	2,857		$	1,205
Issuance of warrants		3,016			—
Exercise of warrants		(1,200	)		—
Change in fair value of warrants during the period		2,268			1,652
Fair value of warrants at end of period	$	6,941		$	2,857

Summary of Warrant Activity

The following is a summary of warrant activity during the year ended December 31, 2017 and nine months ended December 31, 2016:

	Number of Warrants						Weighted-Average Exercise Price
	CAD			US			CAD		US
Outstanding as of April 1, 2016		1,686,000			905,721		$	5.00	$	8.10
Granted		1,030,587			—			7.50
Granted (Agent Compensation)		100,291			—			5.00
Expired		(1,320,880	)		—			5.00
Exercised		(384,468	)		—			5.10
Outstanding as of December 31, 2016		1,111,530			905,721			7.30		8.10
Granted		25,063			646,016			7.50		12.25
Exercised		(125,088	)		(208,333	)		6.50		7.20
Outstanding and exercisable as of December 31, 2017		1,011,505			1,343,404		$	7.38	$	10.25

Warrants Outstanding and Exercisable

The following table summarizes the Company’s warrants outstanding and exercisable as of December 31, 2017:

Number of Warrants Outstanding		Exercise Price	Expiration Date
	90,406	US$15.00	April 30, 2018
	33,546	US$15.00	June 26, 2018
	3,795	US$10.75	June 26, 2020
	12,576	US$15.00	July 17, 2018
	1,509	US$10.75	July 17, 2020
	555,556	US$6.75	December 29, 2018
	961,489	CAD$7.50	April 18, 2019
	50,015	CAD$5.00	April 18, 2018
	270,915	US$12.25	December 22, 2020
	171,020	US$12.25	December 28, 2020
	204,081	US$12.25	December 29, 2020
	2,354,908

April 2016 Offering

Fair Value of Warrants Granted in Offering/Financing Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

The fair value of the warrants granted in the April 2016 Offering were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:


Stock price	CAD$5.45
Exercise price	CAD$7.50
Warrant term	3.0 years
Expected volatility		83.83	%
Risk-free interest rate		0.60	%
Dividend rate		0.00	%

December 2017 Financing

Fair Value of Warrants Granted in Offering/Financing Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions

The fair value of the warrants granted in the December 2017 financing were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	December 22, 2017			December 28, 2017			December 29, 2017
Stock price	$	10.60		$	12.45		$	12.32
Exercise price	$	12.25		$	12.25		$	12.25
Warrant term	3.0 years			3.0 years			3.0 years
Expected volatility		60.24	%		60.24	%		60.24	%
Risk-free interest rate		2.01	%		2.00	%		1.98	%
Dividend rate		0.00	%		0.00	%		0.00	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share Based Payments (Tables)

12 Months Ended

Dec. 31, 2017

Summary of Stock Option Activity

The following is a summary of stock option activity for the year ended December 31, 2017 and nine months ended December 31, 2016:

				Weighted Average		Aggregate
				Exercise Price		Intrinsic Value
	Number of Options			(CAD)		(CAD)
Outstanding as of April 1, 2016		1,335,072		$	5.40	$	1,581
Granted		707,000			6.90
Forfeited		(6,250	)		3.00
Cancelled		(24,822	)		3.00
Exercised		(42,000	)		3.00
Outstanding as of December 31, 2016		1,969,000			6.00		8,218
Granted		868,902			11.15
Forfeited		(153,067	)		11.45
Cancelled		(62,689	)		13.75
Exercised ⁽¹⁾		(173,500	)		5.15
Outstanding as of December 31, 2017		2,448,646		$	7.35	$	21,089
Exercisable as of December 31, 2017		1,451,739		$	5.70	$	14,892

(1) For the year ended December 31, 2017, 20,000 stock options were exercised on a cashless basis resulting in 14,095 common shares being withheld.

Summary of Non-Employee Stock Options Accounted for As Liabilities

The non-employee stock options that are accounted for as liabilities are summarized as follows (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Fair value of non-employee stock options at beginning of period	$	1,617		$	521
Reallocation of vested non-employee stock options		-			268
Exercised		(156	)		-
Cancelled		(294	)		-
Change in fair value of non-employee stock options during the period		1,470			828
Fair value of non-employee stock options at end of period	$	2,637		$	1,617

Summary of Stock-Based Compensation Expense is Classified in Condensed Consolidated Statements of Operations and Comprehensive Loss

Stock-based compensation expense is classified in the Company’s consolidated statements of operations and comprehensive loss as follows (amounts in thousands):

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
Research and development	$	343	$	107
General and administrative		1,475		1,355
	$	1,818	$	1,462

Employee and Director Stock Options

Summary of Stock Options Outstanding and Exercisable

The following table summarizes stock options outstanding and exercisable by employees and directors as of December 31, 2017:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	360,000	June 18, 2019		1.46	$	3.00	$	1.00		360,000
	80,000	June 18, 2019		1.46	$	3.00	$	1.32		80,000
	20,000	December 8, 2019		1.94	$	14.60	$	6.55		20,000
	80,000	December 8, 2019		1.94	$	14.80	$	6.46		80,000
	20,000	March 16, 2020		2.21	$	16.00	$	7.09		20,000
	8,500	August 14, 2020		2.62	$	4.90	$	1.94		8,500
	150,000	October 21, 2020		2.81	$	4.20	$	1.80		112,500
	20,000	December 31, 2020		3.00	$	6.20	$	2.49		20,000
	595,000	July 13, 2020		2.53	$	6.95	$	3.23		396,666
	20,000	August 8, 2020		2.61	$	6.55	$	3.23		10,000
	617,000	April 17, 2027		9.30	$	10.80	$	7.76		-
	6,146	May 18, 2027		9.38	$	10.00	$	5.23		3,073
	10,000	May 18, 2027		9.38	$	10.00	$	7.63		-
	30,000	August 8, 2027		9.61	$	13.15	$	8.86		-
	2,016,646									1,110,739

Estimation Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions

The fair value of employee and director stock options granted for the year ended December 31, 2017 and the nine months ended December 31, 2016 had a weighted average grant date fair value of CAD$4.34 and $2.60 per option, respectively, and they were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Stock price	CAD$10.40			CAD$6.95
Exercise price	CAD$10.85			CAD$6.95
Expected term	6.25 years			2.5 years
Expected volatility		90.84	%		77.92	%
Risk-free interest rate		1.06	%		0.49	%
Dividend rate		0.00	%		0.00	%

Non-employee Stock Options

Summary of Stock Options Outstanding and Exercisable

The following table summarizes stock options outstanding and exercisable by non-employees as of December 31, 2017:

			Options
			Outstanding
Number of			Remaining						Number of
Options			Contractual Life		Exercise		Grant Date Fair		Options
Outstanding		Expiration Date	(In Years)		Price (CAD)		Value (CAD)		Exercisable
	160,000	June 18, 2019		1.46	$	3.00	$	1.32		160,000
	30,000	December 8, 2019		1.94	$	14.60	$	8.25		30,000
	82,000	October 3, 2020		2.76	$	6.75	$	4.00		41,000
	110,000	October 28, 2020		2.83	$	4.20	$	2.20		110,000
	20,000	May 18, 2027		9.38	$	10.00	$	8.69		-
	15,000	August 8, 2027		9.61	$	13.15	$	11.70		-
	15,000	November 6, 2027		9.85	$	20.65	$	19.93		-
	432,000									341,000

Estimation Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions

The fair value of non-employee stock options granted for the year ended December 31, 2017 and the nine months ended December 31, 2016 had a weighted average grant date fair value of CAD$3.88 and $3.23 per option, respectively, and they were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Stock price	CAD$12.15			CAD$9.60
Exercise price	CAD$12.20			CAD$6.75
Option term	10 years			3.75 years
Expected volatility		91.02	%		84.16	%
Risk-free interest rate		1.60	%		0.98	%
Dividend rate		0.00	%		0.00	%

Non-employee Liability

Estimation Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions

	December 31, 2017			December 31, 2016
Stock price	CAD$15.95			CAD$9.60
Exercise price	CAD$4.30			CAD$6.15
Expected life	1.51 years			2.59 years
Expected volatility		61.58	%		87.61	%
Risk-free interest rate		1.61	%		0.79	%
Dividend rate		0.00	%		0.00	%

Restricted Stock Units

Summary of Company’s Restricted Stock Unit Activity

The following is a summary of the Company’s restricted stock unit activity for the year ended December 31, 2017:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit (CAD)
Outstanding as of January 1, 2017		-		$	-
Granted		8,097			10.00
Forfeited		(3,182	)
Outstanding as of December 31, 2017		4,915		$	10.00
Vested as of December 31, 2017 ⁽¹⁾		2,987		$	10.00

(1) includes 723 RSUs withheld for taxes

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following (amounts in thousands):

	December 31, 2017		December 31, 2016
Employees benefits	$	442	$	259
Advance from U.S Army		233		-
Legal expense		343		-
Rent		97		-
Professional services		88		-
Severance		38		-
Other		1		-
	$	1,242	$	259

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Components of Net Loss for Income Tax

The components of net loss are as follows (amounts in thousands):

	Year Ended December 31, 2017		Nine Months Ended December 31, 2016
U.S.	$	24,980	$	11,082
Non-U.S.		3,044		958
	$	28,024	$	12,040

Reconciliation of Income Tax Provision Computed at Statutory Rates

A reconciliation of the income tax provision computed at statutory rates to the reported income tax provision is as follows (amounts in thousands):

	Year Ended December 31, 2017			Nine Months Ended December 31, 2016
Statutory tax rate		34.00	%		34.00	%
Net loss before income taxes	$	28,024		$	12,040
Expected income tax recovery	$	(9,528	)	$	(4,094	)
Increase (decrease) in income tax recovery resulting from:
Derivative liability		1,171			843
Share based payments		453			467
Other permanent difference		(446	)		(420	)
Effect of change in statutory rate		5,938			—
State deferred change		(2,050	)		—
Foreign income taxed at foreign rate		118			77
Increase in valuation allowance		4,344			3,127
Income tax expense	$	—		$	—

Components of Deferred Income Tax Assets and Liabilities

The significant components of the Company’s deferred income tax assets and liabilities after applying enacted corporate tax rates are as follows (amounts in thousands):

	December 31, 2017			December 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$	11,382		$	7,626
Tax credits		1,243			702
Stock compensation		1,414			1,726
Other		530			170
Valuation allowance		(14,569	)		(10,224	)
Net deferred income tax asset	$	—		$	—

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments Related to Non-cancellable Operating Lease Commitments

The future minimum lease payments related to the Company’s non-cancellable operating lease commitments were as follows (amounts in thousands):

For the Year Ending December 31,
2018	$	231
2019		246
2020		253
2021		260
2022		267
Thereafter		12
	$	1,269

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2017

Summary of Private Placement Participation

The following table summarizes their participation (subscription amount in thousands):

	Units Purchased		Subscription Amount
A&B (HK) Company Ltd.		204,081	$	2,000
Director 1		76,530		750
Director 2		51,019		500
CEO		25,510		250
CFO/COO		15,816		155
		372,956	$	3,655

Description of Business - Additional Information (Detail) $ in Thousands		9 Months Ended	12 Months Ended
	Jan. 22, 2018	Dec. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Subsidiary	Mar. 31, 2016 USD ($)
Description Of Business [Line Items]
Date of incorporation			Mar. 13, 2014
Number of wholly-owned subsidiaries \| Subsidiary			2
Cash		$ 2,669	$ 5,562	$ 2,644
Net loss		12,040	28,024
Accumulated deficit		$ 38,345	$ 66,369
Subsequent Event
Description Of Business [Line Items]
Reverse stock split	1-for-5
Reverse stock split, conversion ratio	5

Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)
Schedule Of Significant Accounting Policies [Line Items]
Property, plant and equipment, net \| $	$ 173,000	$ 0
Number of operating segment	1
Number of Reportable Segments	1
Minimum
Schedule Of Significant Accounting Policies [Line Items]
Effective income tax rate	50.00%
Leasehold Improvements
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years
Software \| Minimum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful life	3 years
Software \| Maximum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful life	5 years

Summary of Significant Accounting Policies - Summary of Property, Plant and Equipment (Detail) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 190,000
Less accumulated depreciation	(17,000)
Total	173,000	$ 0
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	173,000
Software
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 17,000

Significant Accounting Policies - Summary of Derivative Financial Instruments for Non-employee Stock Options (Detail) - Fair Value, Measurements, Recurring - Black Scholes Model - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Non-employee Stock Options
Liabilities:
Fair value, liabilities	$ 2,637	$ 1,617
Warrants
Liabilities:
Fair value, liabilities	6,941	2,857
Level 3 \| Non-employee Stock Options
Liabilities:
Fair value, liabilities	2,637	1,617
Level 3 \| Warrants
Liabilities:
Fair value, liabilities	$ 6,941	$ 2,857

Significant Accounting Policies - Summary of Basic and Diluted Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Numerator
Net loss	$ (12,040)	$ (28,024)
Denominator
Weighted-average common shares outstanding - basic and diluted	16,671,019	18,632,740
Basic and diluted net loss per share	$ (0.72)	$ (1.50)

Significant Accounting Policies - Summary of Outstanding Securities Excluded from Computation of Diluted Weighted Shares Outstanding (Details) - shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	3,986,252	4,828,565
Options Outstanding
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	1,969,000	2,448,646
Warrants Outstanding
Antidilutive Securities Excluded from Computation of Earnings per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	2,017,252	2,379,919

Common Stock and Warrants - Additional Information (Detail)													1 Months Ended		9 Months Ended	12 Months Ended
	Dec. 29, 2017 USD ($) shares	Dec. 28, 2017 USD ($) shares	Dec. 22, 2017 USD ($) shares	Jun. 28, 2017 USD ($) shares	Feb. 16, 2017 USD ($) shares	Jun. 06, 2016 USD ($) shares	May 02, 2016 USD ($) shares	May 02, 2016 $ / shares shares	Apr. 18, 2016 USD ($) shares	Apr. 18, 2016 $ / shares shares	Dec. 29, 2015 USD ($) $ / shares shares	Nov. 30, 2015 $ / shares shares	Dec. 31, 2017 USD ($) Tranche $ / shares shares	Nov. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Tranche $ / shares shares	Dec. 31, 2017 $ / shares	Oct. 09, 2015 USD ($)
Schedule Of Stockholders Equity [Line Items]
Class A common share, voting rights																One vote per share
Class A common share, dividends declared																$ 0
Cash issuance cost and commission paid															$ 1,509,000	1,248,000
Gross proceeds from issuance of common stock															$ 7,903,000	$ 20,878,000
Common Stock
Schedule Of Stockholders Equity [Line Items]
Issuance of common stock in public offering \| shares																1,311,000
Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares																	$ 7.50
Warrants expiration date																Apr. 18, 2019
Short Form Prospectus Offering in Canada and U.S. Private Placement
Schedule Of Stockholders Equity [Line Items]
Warrant exercisable price per share \| $ / shares										$ 7.50
Proceeds from issuance of units									$ 7,200,000
Price per share \| $ / shares										$ 5.00
Warrants expiration date																Apr. 18, 2019
Number of common stock converted by each warrant \| shares										1
Cash issuance cost and commission paid									$ 300,000
Options exercisable to purchase units \| shares									87,210
Options exercise price per unit \| $ / shares										$ 5.00
Offering expiration period									24 months
Other cash issuance costs related to offering									$ 1,100,000
Short Form Prospectus Offering in Canada and U.S. Private Placement \| Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Description of units issued																Each Unit consists of one Class A common share in the capital of the Company (a “Common Share’) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”).
Over-Allotment Option
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units							$ 8,100,000
Price per share \| $ / shares								$ 5.00
Warrants expiration date																Apr. 18, 2019
Number of common stock converted by each warrant \| shares								1
Cash issuance cost and commission paid							$ 100,000
Options exercisable to purchase units \| shares							13,081
Options exercise price per unit \| $ / shares								$ 5.00
Offering expiration period							24 months
Number of shares issued in transaction \| shares							218,025
Gross proceeds from issuance of units							$ 900,000
Over-Allotment Option \| Warrants Expiration Date, April 18, 2019
Schedule Of Stockholders Equity [Line Items]
Description of units issued																Each over-allotment warrant entitles the holder thereof to acquire one additional over-allotment Common Share at an exercise price of CAD $7.50 on or before April 18, 2019
Private Placement
Schedule Of Stockholders Equity [Line Items]
Class of warrants exercised \| shares						365,120
Proceeds received from exercise of outstanding warrants						$ 1,400,000
Proceeds from issuance of units													$ 3,655,000
Number of shares issued in transaction \| shares													372,956
Warrants expired unexercised \| shares						1,320,880
Private Placement \| Common Stock
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units				$ 5,400,000
Cash issuance cost and commission paid				$ 9,000
Number of shares issued in transaction \| shares				800,000
Public Offering \| Common Stock
Schedule Of Stockholders Equity [Line Items]
Cash issuance cost and commission paid					$ 1,200,000
Issuance of common stock in public offering \| shares					1,311,000
Gross proceeds from issuance of common stock					$ 9,200,000
December 2017 Financing
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units													$ 6,300,000
Price per share \| $ / shares													$ 9.80			$ 9.80
Description of units issued																Each unit consisted of one share of Class A common stock of the Company at a price of $9.80 per share, and one share purchase warrant.
Number of common stock converted by each warrant \| shares													1			1
Options exercise price per unit \| $ / shares													$ 12.25
Offering expiration period													36 months
Number of shares issued in transaction \| shares													646,016
Number of tranches \| Tranche													3			3
Accrued share issuance cost													$ 100,000			$ 100,000
December 2017 Financing \| Tranche One
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units			$ 2,600,000
Number of shares issued in transaction \| shares			270,915
December 2017 Financing \| Tranche Two
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units		$ 1,700,000
Number of shares issued in transaction \| shares		171,020
December 2017 Financing \| Tranche Three
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units	$ 2,000,000
Number of shares issued in transaction \| shares	204,081
$2.0 million note
Schedule Of Stockholders Equity [Line Items]
Debt conversion, converted instrument, shares issued \| shares												416,666
Common stock conversion price per share \| $ / shares												$ 4.80
Warrants exercisable \| shares												208,333
Warrant exercisable price per share \| $ / shares												$ 7.20
Warrants exercisable period												3 years
Additional funding commitment
Schedule Of Stockholders Equity [Line Items]
Debt conversion, original debt, amount											$ 5,000,000
Debt conversion, converted instrument, shares issued \| shares											1,111,111
Common stock conversion price per share \| $ / shares											$ 4.50
Warrants exercisable \| shares											555,556
Warrant exercisable price per share \| $ / shares											$ 6.75
Warrants exercisable period											3 years
A&B Company Limited
Schedule Of Stockholders Equity [Line Items]
Class of warrants exercised \| shares														208,333
Class of warrant or right exercise price per share \| $ / shares														$ 7.20
Proceeds received from exercise of outstanding warrants														$ 1,500,000
A&B Company Limited \| Private Placement
Schedule Of Stockholders Equity [Line Items]
Proceeds from issuance of units													$ 2,000,000
Number of shares issued in transaction \| shares													204,081
Asset Purchase Agreement \| A&B Company Limited
Schedule Of Stockholders Equity [Line Items]
Convertible promissory note																		$ 7,000,000
Asset Purchase Agreement \| A&B Company Limited \| $2.0 million note
Schedule Of Stockholders Equity [Line Items]
Convertible promissory note																		2,000,000
Asset Purchase Agreement \| A&B Company Limited \| Additional funding commitment
Schedule Of Stockholders Equity [Line Items]
Convertible promissory note																		$ 5,000,000

Common Stock and Warrants - Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions (Detail)				12 Months Ended
	Dec. 29, 2017 $ / shares	Dec. 28, 2017 $ / shares	Dec. 22, 2017 $ / shares	Dec. 31, 2017 $ / shares	Dec. 31, 2016 $ / shares	Dec. 31, 2017 $ / shares
Warrants Granted \| April 2016 Offering
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price						$ 5.45
Exercise price						$ 7.50
Warrant term				3 years
Expected volatility				83.83%
Risk-free interest rate				0.60%
Dividend rate				0.00%
Warrants Granted \| December 2017 Financing
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 12.32	$ 12.45	$ 10.60
Exercise price	$ 12.25	$ 12.25	$ 12.25
Warrant term	3 years	3 years	3 years
Expected volatility	60.24%	60.24%	60.24%
Risk-free interest rate	1.98%	2.00%	2.01%
Dividend rate	0.00%	0.00%	0.00%
Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price				$ 12.32	$ 6.90
Exercise price				$ 10.25	$ 8.10
Warrant term				1 year 10 months 28 days	1 year 10 months 20 days
Expected volatility				62.20%	94.97%
Risk-free interest rate				1.83%	0.79%
Dividend rate				0.00%	0.00%

Common Stock and Warrants - Fair Value of Compensation Options Granted Estimated Using Black-Scholes Option Pricing Model with Weighted Average Assumptions (Detail) - Options - April 2016 Offering	12 Months Ended
	Dec. 31, 2017 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 6.80
Exercise price	$ 5.00
Option term	2 years
Expected volatility	126.76%
Risk-free interest rate	0.61%
Dividend rate	0.00%

Common Stock and Warrants - Summary of Warrants Accounts for as Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair value of warrants at beginning of period	$ 1,205	$ 2,857
Issuance of warrants		3,016
Exercise of warrants		(1,200)
Change in fair value of warrants during the period	1,652	2,268
Fair value of warrants at end of period	$ 2,857	$ 6,941

Common Stock and Warrants - Summary of Warrant Activity (Detail)	9 Months Ended		12 Months Ended
	Dec. 31, 2016 $ / shares shares	Dec. 31, 2016 $ / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2017 $ / shares shares
Class Of Warrant Or Right [Line Items]
Number of Warrants, Outstanding, ending balance			2,354,908	2,354,908
CAD
Class Of Warrant Or Right [Line Items]
Number of Warrants, Outstanding, beginning balance	1,686,000	1,686,000	1,111,530	1,111,530
Number of Warrants, Granted	1,030,587	1,030,587	25,063	25,063
Number of Warrants, Granted (Agent Compensation)	100,291	100,291
Number of Warrants, Expired	(1,320,880)	(1,320,880)
Number of Warrants, Exercised	(384,468)	(384,468)	(125,088)	(125,088)
Number of Warrants, Outstanding, ending balance	1,111,530	1,111,530
Number of Warrants, Outstanding and exercisable, ending balance			1,011,505	1,011,505
Weighted-Average Exercise Price, Outstanding, beginning balance \| $ / shares		$ 5.00		$ 7.30
Weighted-Average Exercise Price, Granted \| $ / shares		7.50		7.50
Weighted-Average Exercise Price, Granted (Agent Compensation) \| $ / shares		5.00
Weighted-Average Exercise Price, Expired \| $ / shares		5.00
Weighted-Average Exercise Price, Exercised \| $ / shares		5.10		6.50
Weighted-Average Exercise Price, Outstanding, ending balance \| $ / shares		$ 7.30
Weighted-Average Exercise Price, Outstanding and exercisable, ending balance \| $ / shares				$ 7.38
USD
Class Of Warrant Or Right [Line Items]
Number of Warrants, Outstanding, beginning balance	905,721	905,721	905,721	905,721
Number of Warrants, Granted			646,016	646,016
Number of Warrants, Exercised			(208,333)	(208,333)
Number of Warrants, Outstanding, ending balance	905,721	905,721
Number of Warrants, Outstanding and exercisable, ending balance			1,343,404	1,343,404
Weighted-Average Exercise Price, Outstanding, beginning balance \| $ / shares	$ 8.10		$ 8.10
Weighted-Average Exercise Price, Granted \| $ / shares			12.25
Weighted-Average Exercise Price, Exercised \| $ / shares			7.20
Weighted-Average Exercise Price, Outstanding, ending balance \| $ / shares	$ 8.10
Weighted-Average Exercise Price, Outstanding and exercisable, ending balance \| $ / shares			$ 10.25

Common Stock and Warrants - Warrants Outstanding and Exercisable (Detail)	12 Months Ended
	Dec. 31, 2017 $ / shares shares	Dec. 31, 2017 $ / shares shares
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	2,354,908	2,354,908
Warrants Expiration Date, April 30, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	90,406	90,406
Exercise Price \| $ / shares	$ 15.00
Expiration Date	Apr. 30, 2018
Warrants Expiration Date, June 26, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	33,546	33,546
Exercise Price \| $ / shares	$ 15.00
Expiration Date	Jun. 26, 2018
Warrants Expiration Date, June 26, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	3,795	3,795
Exercise Price \| $ / shares	$ 10.75
Expiration Date	Jun. 26, 2020
Warrants Expiration Date, July 17, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	12,576	12,576
Exercise Price \| $ / shares	$ 15.00
Expiration Date	Jul. 17, 2018
Warrants Expiration Date, July 17, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	1,509	1,509
Exercise Price \| $ / shares	$ 10.75
Expiration Date	Jul. 17, 2020
Warrants Expiration Date, December 29, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	555,556	555,556
Exercise Price \| $ / shares	$ 6.75
Expiration Date	Dec. 29, 2018
Warrants Expiration Date, April 18, 2019
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	961,489	961,489
Exercise Price \| $ / shares		$ 7.50
Expiration Date	Apr. 18, 2019
Warrants Expiration Date, April 18, 2018
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	50,015	50,015
Exercise Price \| $ / shares		$ 5.00
Expiration Date	Apr. 18, 2018
Warrants Expiration Date, December 22, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	270,915	270,915
Exercise Price \| $ / shares	$ 12.25
Expiration Date	Dec. 22, 2020
Warrants Expiration Date, December 28, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	171,020	171,020
Exercise Price \| $ / shares	$ 12.25
Expiration Date	Dec. 28, 2020
Warrants Expiration Date, December 29, 2020
Class Of Warrant Or Right [Line Items]
Number of Warrants Outstanding	204,081	204,081
Exercise Price \| $ / shares	$ 12.25
Expiration Date	Dec. 29, 2020

Share Based Payments - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2017 USD ($) shares	Jun. 30, 2017	Dec. 31, 2016 USD ($) shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares shares	Aug. 08, 2016 shares	Jun. 18, 2014 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate intrinsic value of stock options exercised \| $			$ 0.1		$ 1.3
Stock options, granted			707,000		868,902
weighted average exercise price \| $ / shares				$ 6.90		$ 11.15
Employee and Director Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options outstanding \| $	$ 4.9		$ 1.3	$ 1.3	$ 4.9	$ 4.9
Weighted-average remaining vesting period			1 year 4 months 28 days		2 years 7 months 6 days
Stock options, granted			625,000		673,902
weighted average exercise price \| $ / shares				$ 6.94		$ 10.87
Weighted average grant date fair value \| $ / shares				$ 2.60		$ 4.34
Non-employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options outstanding \| $	$ 0.4		$ 0.0	$ 0.0	$ 0.4	$ 0.4
Weighted-average remaining vesting period					1 year 11 months 4 days
Stock options, granted			82,000		195,000
weighted average exercise price \| $ / shares				$ 6.70		$ 12.20
Weighted average grant date fair value \| $ / shares				$ 3.23		$ 3.88
Stock options, cancelled or forfeited					185,000
2014 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized and approved to issue under plan								2,421,603
Common stock remaining available for grant	40,000				40,000	40,000
2016 Omnibus Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized and approved to issue under plan							3,000,000
Common stock remaining available for grant	2,693,614				2,693,614	2,693,614
2016 Omnibus Incentive Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate amount of stock excess award	60,000
2016 Omnibus Incentive Plan \| Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		3 years
Vesting percentage		25.00%

Share Based Payments - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands, $ in Millions	9 Months Ended		12 Months Ended
	Dec. 31, 2016 USD ($) shares	Dec. 31, 2016 CAD ($) $ / shares shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2017 CAD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Stock Options, Beginning balance outstanding \| shares	1,335,072	1,335,072	1,969,000	1,969,000
Number of Stock Options, Granted \| shares	707,000	707,000	868,902	868,902
Number of Stock Options, Forfeited \| shares	(6,250)	(6,250)	(153,067)	(153,067)
Number of Stock Options, Cancelled \| shares	(24,822)	(24,822)	(62,689)	(62,689)
Number of Stock Options, Exercised \| shares	(42,000)	(42,000)	(173,500)	(173,500)
Number of Stock Options, Ending balance outstanding \| shares	1,969,000	1,969,000	2,448,646	2,448,646
Number of Stock Options, Exercisable \| shares				1,451,739
Weighted Average Exercise Price, Beginning balance outstanding \| $ / shares		$ 5.40		$ 6.00
Weighted Average Exercise Price, Granted \| $ / shares		6.90		11.15
Weighted Average Exercise Price, Forfeited \| $ / shares		3.00		11.45
Weighted Average Exercise Price, Cancelled \| $ / shares		3.00		13.75
Weighted Average Exercise Price, Exercised \| $ / shares		3.00		5.15
Weighted Average Exercise Price, Ending balance outstanding \| $ / shares		$ 6.00		7.35
Weighted Average Exercise Price, Exercisable \| $ / shares				$ 5.70
Aggregate Intrinsic Value, Beginning balance outstanding \| $		$ 1,581		$ 8,218
Aggregate Intrinsic Value, Exercised \| $	$ 0.1		$ 1.3
Aggregate Intrinsic Value, Ending balance outstanding \| $		$ 8,218		21,089
Aggregate Intrinsic Value, Exercisable \| $				$ 14,892

Share Based Payments - Summary of Stock Option Activity (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2017 shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock options exercised on cashless basis	20,000
Number of common stock shares withheld	14,095

Share Based Payments - Summary of Stock Options Outstanding and Exercisable (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding	1,969,000	2,448,646	1,335,072
Exercise Price	$ 6.00	$ 7.35	$ 5.40
Number of Options Exercisable		1,451,739
Employee and Director Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		2,016,646
Grant Date Fair Value	2.60	$ 4.34
Number of Options Exercisable		1,110,739
Employee and Director Stock Options \| Option One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		360,000
Expiration Date		Jun. 18, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 5 months 15 days
Exercise Price		$ 3.00
Grant Date Fair Value		$ 1.00
Number of Options Exercisable		360,000
Employee and Director Stock Options \| Option Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		80,000
Expiration Date		Jun. 18, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 5 months 15 days
Exercise Price		$ 3.00
Grant Date Fair Value		$ 1.32
Number of Options Exercisable		80,000
Employee and Director Stock Options \| Option Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		20,000
Expiration Date		Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 11 months 8 days
Exercise Price		$ 14.60
Grant Date Fair Value		$ 6.55
Number of Options Exercisable		20,000
Employee and Director Stock Options \| Option Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		80,000
Expiration Date		Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 11 months 8 days
Exercise Price		$ 14.80
Grant Date Fair Value		$ 6.46
Number of Options Exercisable		80,000
Employee and Director Stock Options \| Option Five
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		20,000
Expiration Date		Mar. 16, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 2 months 15 days
Exercise Price		$ 16.00
Grant Date Fair Value		$ 7.09
Number of Options Exercisable		20,000
Employee and Director Stock Options \| Option Six
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		8,500
Expiration Date		Aug. 14, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 7 months 13 days
Exercise Price		$ 4.90
Grant Date Fair Value		$ 1.94
Number of Options Exercisable		8,500
Employee and Director Stock Options \| Option Seven
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		150,000
Expiration Date		Oct. 21, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 9 months 21 days
Exercise Price		$ 4.20
Grant Date Fair Value		$ 1.80
Number of Options Exercisable		112,500
Employee and Director Stock Options \| Option Eight
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		20,000
Expiration Date		Dec. 31, 2020
Options Outstanding Remaining Contractual Life (In Years)		3 years
Exercise Price		$ 6.20
Grant Date Fair Value		$ 2.49
Number of Options Exercisable		20,000
Employee and Director Stock Options \| Option Nine
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		595,000
Expiration Date		Jul. 13, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 6 months 10 days
Exercise Price		$ 6.95
Grant Date Fair Value		$ 3.23
Number of Options Exercisable		396,666
Employee and Director Stock Options \| Option Ten
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		20,000
Expiration Date		Aug. 08, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 7 months 9 days
Exercise Price		$ 6.55
Grant Date Fair Value		$ 3.23
Number of Options Exercisable		10,000
Employee and Director Stock Options \| Option Eleven
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		617,000
Expiration Date		Apr. 17, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 3 months 18 days
Exercise Price		$ 10.80
Grant Date Fair Value		$ 7.76
Employee and Director Stock Options \| Option Twelve
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		6,146
Expiration Date		May 18, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 4 months 17 days
Exercise Price		$ 10.00
Grant Date Fair Value		$ 5.23
Number of Options Exercisable		3,073
Employee and Director Stock Options \| Option Thirteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		10,000
Expiration Date		May 18, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 4 months 17 days
Exercise Price		$ 10.00
Grant Date Fair Value		$ 7.63
Employee and Director Stock Options \| Option Fourteen
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		30,000
Expiration Date		Aug. 08, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 7 months 9 days
Exercise Price		$ 13.15
Grant Date Fair Value		$ 8.86
Non-employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		432,000
Grant Date Fair Value	$ 3.23	$ 3.88
Number of Options Exercisable		341,000
Non-employee Stock Options \| Option One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		160,000
Expiration Date		Jun. 18, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 5 months 15 days
Exercise Price		$ 3.00
Grant Date Fair Value		$ 1.32
Number of Options Exercisable		160,000
Non-employee Stock Options \| Option Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		30,000
Expiration Date		Dec. 08, 2019
Options Outstanding Remaining Contractual Life (In Years)		1 year 11 months 8 days
Exercise Price		$ 14.60
Grant Date Fair Value		$ 8.25
Number of Options Exercisable		30,000
Non-employee Stock Options \| Option Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		82,000
Expiration Date		Oct. 03, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 9 months 3 days
Exercise Price		$ 6.75
Grant Date Fair Value		$ 4.00
Number of Options Exercisable		41,000
Non-employee Stock Options \| Option Four
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		110,000
Expiration Date		Oct. 28, 2020
Options Outstanding Remaining Contractual Life (In Years)		2 years 9 months 29 days
Exercise Price		$ 4.20
Grant Date Fair Value		$ 2.20
Number of Options Exercisable		110,000
Non-employee Stock Options \| Option Five
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		20,000
Expiration Date		May 18, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 4 months 17 days
Exercise Price		$ 10.00
Grant Date Fair Value		$ 8.69
Non-employee Stock Options \| Option Six
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		15,000
Expiration Date		Aug. 08, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 7 months 9 days
Exercise Price		$ 13.15
Grant Date Fair Value		$ 11.70
Non-employee Stock Options \| Option Seven
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding		15,000
Expiration Date		Nov. 06, 2027
Options Outstanding Remaining Contractual Life (In Years)		9 years 10 months 6 days
Exercise Price		$ 20.65
Grant Date Fair Value		$ 19.93

Share Based Payments - Schedule of Fair Value of Employee and Director Stock Options Granted Estimated Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions (Details) - Employee and Director Stock Options - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 6.95	$ 10.40
Exercise price	$ 6.95	$ 10.85
Expected term	2 years 6 months	6 years 3 months
Expected volatility	77.92%	90.84%
Risk-free interest rate	0.49%	1.06%
Dividend rate	0.00%	0.00%

Share Based Payments - Schedule of Fair Value of Non-Employee Stock Options Granted Estimated Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions (Details) - Non-employee Stock Options - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 9.60	$ 12.15
Exercise price	$ 6.75	$ 12.20
Expected term	3 years 9 months	10 years
Expected volatility	84.16%	91.02%
Risk-free interest rate	0.98%	1.60%
Dividend rate	0.00%	0.00%

Share Based Payments - Summary of Non-Employee Stock Options Required to be Accounted for As Liabilities (Detail) - Non-employee Stock Options - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of non-employee stock options at beginning of period	$ 521	$ 1,617
Reallocation of vested non-employee stock options	268
Exercised		(156)
Cancelled		(294)
Change in fair value of non-employee stock options during the period	828	1,470
Fair value of non-employee stock options at end of period	$ 1,617	$ 2,637

Share Based Payments - Schedule of Fair Value of Non-Employee Liability Classified Award Estimated Using Black-Scholes Option Pricing Model With Following Weighted Average Assumptions (Details) - Non-employee Liability - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock price	$ 9.60	$ 15.95
Exercise price	$ 6.15	$ 4.30
Expected term	2 years 7 months 2 days	1 year 6 months 3 days
Expected volatility	87.61%	61.58%
Risk-free interest rate	0.79%	1.61%
Dividend rate	0.00%	0.00%

Share Based Payments - Summary of Company's Restricted Stock Unit Activity (Detail) - Restricted Stock Units	12 Months Ended
	Dec. 31, 2017 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Restricted Stock Units, Granted	8,097
Number of Restricted Stock Units, Forfeited	(3,182)
Number of Restricted Stock Units, Ending balance outstanding	4,915
Number of Restricted Stock Units, Vested	2,987
Weighted Average Grant Date Fair Value per Unit, Granted \| $ / shares	$ 10.00
Weighted Average Grant Date Fair Value per Unit, Ending balance outstanding \| $ / shares	10.00
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	$ 10.00

Share Based Payments - Summary of Company's Restricted Stock Unit Activity (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2017 shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of RSUs withheld for taxes	723

Share Based Payments - Summary of Stock Based Compensation Expense is Classified in Statement of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,462	$ 1,818
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	107	343
General and Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,355	$ 1,475

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Employees benefits	$ 442	$ 259
Advance from U.S Army	233
Legal expense	343
Rent	97
Professional services	88
Severance	38
Other	1
Total accrued expenses	$ 1,242	$ 259

Income Taxes - Components of Net Loss for Income Tax (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Components Of Income Tax Expense Benefit Continuing Operations [Abstract]
U.S.	$ 11,082	$ 24,980
Non-U.S.	958	3,044
Loss before income taxes	$ 12,040	$ 28,024

Income Taxes - Reconciliation of Income Tax Provision Computed at Statutory Rates (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory tax rate	34.00%	34.00%
Net loss before income taxes	$ 12,040	$ 28,024
Expected income tax recovery	(4,094)	(9,528)
Increase (decrease) in income tax recovery resulting from:
Derivative liability	843	1,171
Share based payments	467	453
Other permanent difference	(420)	(446)
Effect of change in statutory rate		5,938
State deferred change		(2,050)
Foreign income taxed at foreign rate	77	118
Increase in valuation allowance	$ 3,127	$ 4,344

Income Taxes - Components of Deferred Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred income tax assets (liabilities)
Operating losses carried forward	$ 11,382	$ 7,626
Tax credits	1,243	702
Stock compensation	1,414	1,726
Other	530	170
Valuation allowance	$ (14,569)	$ (10,224)

Income Taxes - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Line Items]
Net operating loss, domestic			$ 39,000,000
Operating loss carry forwards expiration year			2033
Corporate tax rate	34.00%		34.00%
Tax cuts and jobs act, reduction in deferred tax assets			$ 5,900,000
Tax cuts and jobs act, reduction in valuation allowance			5,900,000
Tax cuts and jobs act, income tax provision			0
Accrual relating to uncertain tax positions			$ 0
Scenario, Plan
Income Taxes [Line Items]
Corporate tax rate		21.00%
Maximum
Income Taxes [Line Items]
Corporate tax rate			35.00%
Canada
Income Taxes [Line Items]
Accumulated non-capital losses in Canada			$ 6,000,000

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended			12 Months Ended
	Dec. 29, 2017	Jan. 22, 2013	Jul. 31, 2017	Mar. 31, 2017	Nov. 30, 2014	Dec. 31, 2017	Oct. 30, 2017
Commitments And Contingencies [Line Items]
Lease commencement date			Jul. 17, 2017	Jul. 01, 2017
Lease termination date			Jan. 16, 2023	Dec. 31, 2022
Lease option to extend termination year				2027
Lease option to extend termination date			Jan. 31, 2028
Lease monthly rent plus utilities			$ 20,000
Lease monthly rent plus utilities beginning date			Jan. 31, 2018
Lease annual increase in rental percentage			3.00%
Advanced NeuroRehabilitation, LLC \| License Agreement for Exclusive Right on Patent Pending Technology
Commitments And Contingencies [Line Items]
Issuance of common stock for license agreement		3,207,005
Percentage of royalty on net revenue		4.00%
A&B Company Limited \| Asset Purchase Agreement
Commitments And Contingencies [Line Items]
Contract penalty payable on failure to obtain FDA clearance							$ 2,000
Altair LLC
Commitments And Contingencies [Line Items]
Percentage of royalty on sales					7.00%
Key Tronic Corporation \| Manufacturing and Supply Agreement
Commitments And Contingencies [Line Items]
Agreement description						On December 29, 2017, NHC, a wholly owned subsidiary of the Company entered into a Manufacturing and Supply Agreement (“MSA”) with Key Tronic Corporation (“Key Tronic”), for the manufacture and supply of the Company’s PoNS device based upon the Company’s product specifications as set forth in the MSA. Per the agreement, the Company shall provide to Key Tronic a rolling forecast for the procurement of parts and material and within normal lead times based on estimated delivery dates for the manufacture of the PoNS device. The term of the agreement will be for three-years and will automatically renew for additional consecutive terms of one year, unless cancelled by either party upon 180-day written notice to the other party prior to the end of the then current term. As of December 31, 2017, no initial forecast had been provided to Key Tronic by the Company.
Agreement term	3 years
Agreement auto renewal period	1 year
Notice period to cancel the renewal of agreement	180 days

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Related to Non-cancellable Operating Lease Commitments (Detail) $ in Thousands	Dec. 31, 2017 USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2018	$ 231
2019	246
2020	253
2021	260
2022	267
Thereafter	12
Future minimum lease payments, total	$ 1,269

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2016	Dec. 31, 2016	Dec. 31, 2017
Related Party Transaction [Line Items]
Change in fair value of derivative financial instruments		$ (2,480)	$ (3,443)
Non-employee Stock Options
Related Party Transaction [Line Items]
Change in fair value of derivative financial instruments		(200)	$ (400)
Minimum \| A&B (HK) Company Ltd.
Related Party Transaction [Line Items]
Ownership percentage of common stock shares outstanding			5.00%
Directors
Related Party Transaction [Line Items]
Consulting fees paid		100	$ 16
Montel Media, Inc. \| Minimum
Related Party Transaction [Line Items]
Beneficially owns common stock percentage			5.00%
Montel Media, Inc. \| Consulting Agreement
Related Party Transaction [Line Items]
Consulting fees paid		100	$ 200
Consulting monthly fee	$ 15
Clinvue LLC
Related Party Transaction [Line Items]
Consulting fees paid		$ 0	$ 100
CEO \| Minimum
Related Party Transaction [Line Items]
Ownership percentage of common stock shares outstanding			5.00%
CFO/CEO \| Minimum
Related Party Transaction [Line Items]
Ownership percentage of common stock shares outstanding			5.00%
Director 1 \| Minimum
Related Party Transaction [Line Items]
Ownership percentage of common stock shares outstanding			5.00%
Director 2 \| Minimum
Related Party Transaction [Line Items]
Ownership percentage of common stock shares outstanding			5.00%

Related Party Transactions - Summary of Private Placement Participation (Detail) - Private Placement $ in Thousands	1 Months Ended
	Dec. 31, 2017 USD ($) shares
Related Party Transaction [Line Items]
Units Purchased \| shares	372,956
Subscription Amount \| $	$ 3,655
A&B (HK) Company Ltd.
Related Party Transaction [Line Items]
Units Purchased \| shares	204,081
Subscription Amount \| $	$ 2,000
Director 1
Related Party Transaction [Line Items]
Units Purchased \| shares	76,530
Subscription Amount \| $	$ 750
Director 2
Related Party Transaction [Line Items]
Units Purchased \| shares	51,019
Subscription Amount \| $	$ 500
CEO
Related Party Transaction [Line Items]
Units Purchased \| shares	25,510
Subscription Amount \| $	$ 250
CFO/CEO
Related Party Transaction [Line Items]
Units Purchased \| shares	15,816
Subscription Amount \| $	$ 155

Sole-Source Cost-Sharing Agreement and Cooperative Research and Development Agreement - Additional Information (Detail) - USAMRMC - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 07, 2017	Jul. 31, 2015	Sep. 30, 2017	Dec. 31, 2017
Schedule Of Cost Sharing Agreement And Cooperative Research And Development Agreement [Line Items]
Expiration date of original contract				Dec. 31, 2016
Reimbursement received				$ 3,000,000
Reimbursement received recorded as advance against final milestone				$ 200,000
Extended expiration date of original contract	Dec. 31, 2018
Maximum
Schedule Of Cost Sharing Agreement And Cooperative Research And Development Agreement [Line Items]
Reimbursable trial cost		$ 3,000,000
Cooperative Research and Development Agreement
Schedule Of Cost Sharing Agreement And Cooperative Research And Development Agreement [Line Items]
Extended expiration date of original contract			Dec. 31, 2021
Expiration year of original contract			2018

Subsequent Events - Additional Information (Detail) - Subsequent Event - Warrants - A&B Company Limited $ / shares in Units, $ in Millions	1 Months Ended
	Feb. 28, 2018 USD ($) $ / shares shares
Subsequent Event [Line Items]
Warrants exercised \| shares	555,556
Exercise price of warrants \| $ / shares	$ 6.75
Issuance date of warrants	Jan. 07, 2016
Gross proceeds of warrants \| $	$ 3.8